HOME > BUSINESS
BUSINESS
- Nippon Shinyaku Preparing for Clinical Studies of 5 Oligonucleotide Drugs to Cover 50% of DMD Patients: Pres.
November 8, 2018
- Takeda Launches Entyvio in Japan for Ulcerative Colitis
November 8, 2018
- Aspen Taking Over Anexate from Astellas
November 7, 2018
- Kyowa Kirin License Novel Blood Cancer Treatment from US Company
November 7, 2018
- EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
November 7, 2018
- Balancing Act: All Eyes on Nesp Biosame Pricing before June 2019 Listing, Biosimilars to Follow in November
November 5, 2018
- Opdivo-Yervoy Combo Gets RCC Nod in Taiwan
November 5, 2018
- Kyowa Kirin to Start US PI Study on IDO Inhibitor-Bavencio Combo
November 5, 2018
- 8 Major Drug Makers See Flat Sales in 1st Half; Overseas Growth Continues to Compensate for Slumping Japan Revenue
November 5, 2018
- Pfizer Files Vyndaqel for Sakigake-Designated Transthyretin Amyloid Cardiomyopathy Indication in Japan
November 5, 2018
- JCR’s Fabrazyme Biosimilar to Enter NHI Price List as Early as November
November 5, 2018
- Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
- Eisai, Merck to Start Lenvima Commercial Collaboration in Major Markets by March-End
November 2, 2018
- Eisai’s 1st Half Operating Profit Zooms 74% on Lenvima Boon
November 2, 2018
- Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
November 2, 2018
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ribomic Launches PI/IIa Study of Anti-FGF2 Aptamer in US for AMD
November 2, 2018
- Astellas Investing 30 Billion Yen in R&D, Production Facilities Catering to Multiple Modalities
November 1, 2018
- Japan Needs New Pricing Model for Gene Therapies: Astellas Chief
November 1, 2018
- Astellas Sales Rep Number Now at 2,100; Redundancy Program Gets Underway
November 1, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
